Loading...
Cardiovascular disease (CVD) remains the leading cause of death in U.S. women; moreover, since 1983, more women than men have died of CVD annually.1 In secondary prevention settings, statins reduce risk for recurrent CVD events and CVD mortality, with benefits of comparable magnitude in men and women.2 Although primary prevention studies have shown that statin therapy lowers the incidence of cardiovascular events by about 20%, the study populations predominantly included men; hence, questions remain about the efficacy and safety of statins for preventing CVD in women.
CVD primary prevention trials have been grossly underpowered with respect to enrollment of women, limiting the ability to stratify results by sex. This lack o…